AlixaRx Revenue and Competitors

Dallas, TX USA

Location

$100M

Total Funding

Estimated Revenue & Valuation

  • AlixaRx's estimated annual revenue is currently $39M per year.(i)
  • AlixaRx's estimated revenue per employee is $150,500
  • AlixaRx's total funding is $100M.

Employee Data

  • AlixaRx has 259 Employees.(i)
  • AlixaRx grew their employee count by 0% last year.

AlixaRx's People

NameTitleEmail/Phone
1
VP Human ResourcesReveal Email/Phone
2
VPReveal Email/Phone
3
Financial Systems DirectorReveal Email/Phone
4
Business Development DirectorReveal Email/Phone
5
Regional Sales DirectorReveal Email/Phone
6
DirectorReveal Email/Phone
7
Regional Sales DirectorReveal Email/Phone
8
Pharmacy ManagerReveal Email/Phone
9
Operations Manager IIReveal Email/Phone
10
Finance ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.4M12-29%$11.4MN/A
#2
$0.5M17-23%$10.2MN/A
#3
$1.3M15-12%N/AN/A
#4
$17.2M123N/AN/AN/A
#5
$0.1M60%$4.7MN/A
#6
$14.1M101-6%$42.3MN/A
#7
$1.2M1427%N/AN/A
#8
$1M120%N/AN/A
#9
$182.3M9305%N/AN/A
#10
$22M143-14%N/AN/A
Add Company

What Is AlixaRx?

Our new pharmacy and clinical pharmacist services company was created with the direct input of patients, nurses, therapists, physicians and pharmacists. It was a collaboration of innovative thinking focused on improving access, increasing safety and maximizing time and cost savings.

keywords:Biotechnology

$100M

Total Funding

259

Number of Employees

$39M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AlixaRx News

2013-07-02 - AlixaRx Receives $100M in Capital from Fillmore Capital Partners

AlixaRx, a Dallas-based provider of advanced pharmacy services in post-acute health care facilities, received $100m in capital from Fillmore Capital Partners. A spin-off of Drumm Corp., the company leverages technology to deliver medication therapy management. AlixaRx operates full-service phar ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$60.1M2605%N/A
#2
$37M264172%N/A
#3
$42.7M2656%$73M
#4
$77.3M268325%N/A
#5
$80.2M27038%N/A